Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement

• Status: Not yet recruiting
• Trial end date: 2022-09-15
• Target enrollment: 0
• Participant gender: All

Summary

Proportional dose of sublingual fentanyl tablet (Narco®) based on daily opioid requirement versus intravenous PCA for breakthrough cancer pain: A prospective, randomized, open-label, noninferiority trial.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University

Criteria

Inclusion Criteria:

• Age 19-80

• Cancer pain

• Admission for the control of cancer pain or consultation for the treatment of cancer pain

• Stable vital sign

• ECOG status ≤ 3 for more than 1 or 2 months

• Opioid-tolerant state

• No history of using sublingual fentanyl

Exclusion Criteria:

• Noncancer pain

• Opioid naive

• baseline NRS pain score> 4

• Current using sublingual fentanyl

• Difficult to assess cancer pain

• no evidence of disease(cancer)

• Planned surgical resection of cancer

• Allergy to fentanyl

• Severe renal and/or liver function

• Severe respiratory depression or uncontrolled COPD